Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:3:2059.
doi: 10.1038/srep02059.

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men

Emma Killick  1 , Richard Morgan, Francesca Launchbury, Elizabeth Bancroft, Elizabeth Page, Elena Castro, Zsofia Kote-Jarai, Armen Aprikian, Ignacio Blanco, Virginia Clowes, Susan Domchek, Fiona Douglas, Diana Eccles, D Gareth Evans, Marion Harris, Judy Kirk, Jimmy Lam, Geoffrey Lindeman, Gillian Mitchell, Nicholas Pachter, Christina Selkirk, Kathy Tucker, Janaz Zgajnar, Rosalind Eeles, Hardev Pandha
Affiliations

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men

Emma Killick et al. Sci Rep. 2013.

Abstract

Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Association between serum PSA and urinary EN2.
See this image and copyright information in PMC

References

    1. Siegel R., Naishadham D. & Jemal A. Cancer statistics, 2012. CA Cancer J Clin 62, 10–29 (2012). - PubMed
    1. South West Public Health Observatory. SWPHO Briefing: Prostate cancer survival by stage, <http://www.swpho.nhs.uk/resource/item.aspx?RID=41287> (2008). Date accessed 15.07.11.
    1. Andriole G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360, 1310–1319 (2009). - PMC - PubMed
    1. Schroder F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360, 1320–1328 (2009). - PubMed
    1. Goh C. L. et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 271, 353–365 (2012). - PubMed

Publication types